All News

Researchers review the safety, efficacy, and considerations for COVID-19 vaccination in multiple sclerosis patients, especially those on disease-modifying therapies, affirming the vaccine's overall benefit in reducing severe COVID-19 risks without significantly increasing MS relapse rates.

Tislelizumab's inclusion in the National Comprehensive Cancer Network (NCCN) guidelines for hepatocellular carcinoma (HCC) as a category 1 recommendation marks an advancement in the treatment landscape for HCC.

COVID-19 vaccination significantly reduced anxiety and depression in patients with idiopathic pulmonary fibrosis (IPF), improving their mental health one month after the first dose.

Phase 2 data show about half of patients with high-risk or secondary acute myeloid leukemia achieved a complete response or complete response with incomplete hematologic recovery after one or two cycles of induction therapy with CPX-351.

This analysis provides much-needed robust data on the efficacy of heat-cold therapy for mitigating discomfort and insomnia in restless legs syndrome (RSL).

Deuruxolitinib showed significant efficacy and safety in hair regrowth stimulation among adult patients with alopecia areata, particularly in those with moderate to severe hair loss.

The Center on Health Equity & Access highlights news and expert insights on research, social determinants of health, and health policy.

The findings show that increases in serum glial fibrillary acidic protein throughout B-cell depletion therapy are associated with disability worsening despite not relapsing—known as progression independent of relapse activity.

Sandra Cuellar, PharmD, from the University of Illinois Chicago, highlights the critical role of real-world data in shaping reimbursement models for oncology therapies and emphasizes the growing importance of patient-centered care through shared decision-making, precision medicine, and patient-reported outcomes.

Despite found associations, due to small sample sizes the researchers suggest readers interpret their findings with caution.

High cumulative doses of epipodophyllotoxins were associated with the highest risk for survivors of childhood cancer of developing late subsequent leukemia.

With ponatinib (Iclusig) receiving an accelerated approval from the FDA earlier this year for the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), updated guidelines could be on the horizon.

November is Diabetic Eye Disease Awareness Month. Diabetes is the leading cause of preventable blindness in the US. Here is a look at recent research related to diabetic eye diseases.

Matias Sanchez, MD, assistant professor in the Department of Medicine, Division of Hematology and Oncology, University of Illinois Chicago, emphasizes the importance of patient education and caregiver involvement in managing complex therapies and advises oncologists to confidently integrate advanced treatments.

While the Medicare Competitive Bidding Program reduced spending, it did not significantly impact supplemental oxygen use or clinical outcomes among patients with chronic obstructive pulmonary disease (COPD).

Elacestrant, a selective estrogen receptor degrader, demonstrated significant improvements in progression-free survival (PFS) compared with standard-of-care treatments for patients with ER-positive, HER2-negative, ESR1-mutated metastatic breast cancer.

Divya Gupta, MD, assistant professor at Feinberg School of Medicine at Northwestern University, discussed the potential of using circulating tumor DNA and minimal residual disease (MRD) assays for personalized treatment in non–small cell lung cancer (NSCLC), while emphasizing the unmet need for effective second-line therapies for patients without driver mutations.

Food insecurity is a significant public health concern that disproportionately affects marginalized communities, contributing to a range of health disparities.

The European Commission has approved mirvetuximab soravtansine for select patients with pretreated folate receptor–alpha (FRα)-positive, platinum-resistant ovarian cancer.

Investigators said patients experienced adverse effects in line with those expected for myeloablative conditioning with busulfan following treatment with betibeglogene autotemcel (beti-cel; Zynteglo; bluebird bio).

The single-center report showed the therapy had a favorable safety profile and manageable side effects in children with relapsed or refractory (R/R) acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS).

While name brands like Adderall and Vyvanse may have been recently removed from the FDA Drug Shortage Database, it's unclear if it'll last; meanwhile, many generic forms of attention-deficit/hyperactivity disorder (ADHD) medication are still in short supply.

Patients with amblyopia had a statistically significant improvement in their visual acuity after binocular rehabilitation through digital video games.

A study in Japan found that antifibrotic treatment rates for patients with idiopathic pulmonary fibrosis (IPF) varied by medical facility, with higher treatment rates observed in referral hospitals than in general hospitals or clinics.

The authors emphasize the value of subgroup analyses for tracking patterns in spinal muscular atrophy (SMA), as opposed to drawing mean conclusions across entire cohorts.

The 2025 Global Initiative for Chronic Obstructive Lung Disease (GOLD) report highlighted climate change, cardiovascular risk, and pulmonary hypertension.

Accompanying these findings is a call for refined treatment strategies that have potential to better outcomes among patients who have unresectable stage III non–small cell lung cancer (NSCLC).

The Stanford professor was a supporter of herd immunity during the COVID-19 pandemic.

State-level maternal health scores varied greatly in the 2024 March of Dimes report card, with Vermont getting the only A grade on preterm birth rates.

If made official, the proposed rule would give Part D and Medicaid beneficiaries expanded coverage to antiobesity drugs starting in 2026.